KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Change in Cash (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Change in Cash for 9 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 7616.67% year-over-year to $1.4 billion, compared with a TTM value of $256.0 million through Dec 2025, up 245.95%, and an annual FY2025 reading of $256.0 million, up 245.95% over the prior year.
  • Change in Cash was $1.4 billion for Q4 2025 at Teva Pharmaceutical Industries, up from $42.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $1.4 billion in Q4 2025 and bottomed at -$1.6 billion in Q1 2025.
  • Average Change in Cash over 5 years is $69.0 million, with a median of $47.0 million recorded in 2022.
  • The sharpest move saw Change in Cash tumbled 1365.38% in 2023, then soared 7616.67% in 2025.
  • Year by year, Change in Cash stood at $153.0 million in 2021, then skyrocketed by 276.47% to $576.0 million in 2022, then skyrocketed by 69.62% to $977.0 million in 2023, then tumbled by 101.84% to -$18.0 million in 2024, then skyrocketed by 7616.67% to $1.4 billion in 2025.
  • Business Quant data shows Change in Cash for TEVA at $1.4 billion in Q4 2025, $42.0 million in Q3 2025, and $464.0 million in Q2 2025.